GGrantIndex
← Search

Transgenic & Knockout Shared Resource

$113,545P30FY2023CANIH

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications, trials & patents

Trial NCT06508463Trial NCT06387979Trial NCT06381154Trial NCT06353191Trial NCT06315595Trial NCT06271291Trial NCT06238648Trial NCT06207188Trial NCT06160206Trial NCT06115772Trial NCT06078709Trial NCT06075524Trial NCT06073951Trial NCT06058663Trial NCT05917145Trial NCT05910801Trial NCT05720624Trial NCT05717153Trial NCT05704283Trial NCT05703399Trial NCT05674123Trial NCT05653661Trial NCT05640765Trial NCT05612100Trial NCT05591092Trial NCT05584449Trial NCT05575440Trial NCT05560009Trial NCT05557877Trial NCT05556525Trial NCT05549661Trial NCT05547386Trial NCT05547347Trial NCT05541016Trial NCT05530759Trial NCT05526417Trial NCT05523154Trial NCT05518903Trial NCT05512767Trial NCT05507879Trial NCT05507541Trial NCT05497804Trial NCT05465954Trial NCT05465941Trial NCT05447923Trial NCT05447910Trial NCT05443971Trial NCT05438563Trial NCT05417867Trial NCT05416983Trial NCT05412953Trial NCT05411523Trial NCT05411497Trial NCT05410977Trial NCT05407038Trial NCT05407025Trial NCT05403580Trial NCT05399004Trial NCT05393713Trial NCT05392946Trial NCT05388877Trial NCT05388851Trial NCT05388058Trial NCT05388006Trial NCT05356897Trial NCT05294367Trial NCT05288062Trial NCT05269381Trial NCT05246670Trial NCT05232851Trial NCT05224271Trial NCT05222620Trial NCT05212428Trial NCT05199285Trial NCT05194293Trial NCT05176223Trial NCT05168163Trial NCT05130060Trial NCT05112627Trial NCT05112614Trial NCT05111314Trial NCT05077735Trial NCT05075980Trial NCT05053100Trial NCT05045066Trial NCT05033288Trial NCT05030298Trial NCT05018208Trial NCT05005182Trial NCT04999826Trial NCT04975516Trial NCT04967196Trial NCT04926948Trial NCT04925817Trial NCT04917744Trial NCT04906369Trial NCT04897009Trial NCT04895735Trial NCT04892277Trial NCT04892264

Abstract

TRANSGENIC AND KNOCKOUT SHARED RESOURCE PROJECT SUMMARY The main purpose of the Mayo Clinic Cancer Center Transgenic and Knockout (TKO) Shared Resource is to assist investigators at all 3 sites with the design and the generation of genetically modified mouse models. Utilization of the resource has been strong with 49 Cancer Center members from 8 different Programs using the Shared Resource during the current funding period (2013-2017). Our services include CRISPR/Cas9 mediated editing of genes of interest in fertilized mouse eggs to generate knockout and knock-in mouse models to inactivate or tag it, or to introduce point mutations, reporter genes, loxP sites or large deletions. Although gene editing by CRISPR/Cas9 is incredibly useful, in some instances it is not as robust as conventional gene targeting in embryonic stem (ES) cells, prompting us to maintain our classical services mainly to insert large (>5 kb) DNA fragments and loxP sites. Additional services offered by the TKO Core include founder screening, founder breeding, sperm cryopreservation, recovery of cryopreserved mouse strains through in vitro fertilization, and standard histopathology. TKO Shared Resource staff also provide advice on DNA preparation, mouse genotyping, handling and husbandry. To stay at the cutting edge of genome editing, the TKO devotes time and effort to develop or implement innovative and experimental procedures. The above activities allow Cancer Center members to implement state-of-the-art mouse models to address key open questions in the field of cancer etiology and to design and test new therapeutic approaches that improve cancer treatment outcome. The TKO Shared Resource achieved a score of Outstanding at the previous site visit.

View original record on NIH RePORTER →